Tony Punturieri, M.D., Ph.D. Telephone: 301-435-0230 FOA RFA-HL-16-012: Health Outcomes Trial.
-
Upload
allan-price -
Category
Documents
-
view
220 -
download
0
description
Transcript of Tony Punturieri, M.D., Ph.D. Telephone: 301-435-0230 FOA RFA-HL-16-012: Health Outcomes Trial.
Tony Punturieri, M.D., Ph.D.Telephone: 301-435-0230Email: [email protected]
FOA RFA-HL-16-012:Health Outcomes Trial (UM1)
Household Air Pollution (HAP) Trial
Household Air Pollution in Low- and Middle-Income Countries: Health Risks and Research Priorities
William J. Martin, II1*, Roger I. Glass2, Houmam Araj3, John Balbus4, Francis S. Collins5, Siaˆ n Curtis6, Gregory B. Diette7, William N. Elwood8, Henry Falk9, Patricia L. Hibberd10, Susan E. J. Keown11, Sumi Mehta12, Erin Patrick13, Julia Rosenbaum14, Amir Sapkota15, H. Eser Tolunay16, Nigel G. Bruce17
1 Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America, 2 John E. Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States of America, 3 National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States of America, 4 National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, United States of America, 5 National Institutes of Health, Bethesda, Maryland, United States of America, 6 MEASURE Evaluation Project at the Carolina Population Center and the Department of Maternal and Child Health, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America, 7 School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America, 8 Office of Behavioral and Social Sciences Research, National Institutes of Health, Bethesda, Maryland, United States of America, 9 Office of Noncommunicable Diseases, Injury and Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 10 Division of Global Health, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 11 Palladian Partners, Silver Spring, Maryland, United States of America, 12 Global Alliance for Clean Cookstoves, Washington, District of Columbia, United States of America, 13 Women’s Refugee Commission, New York, New York, United States of America, 14 FHI 360, Washington, District of Columbia, United States of America, 15 School of Public Health, University of Maryland, College Park, Maryland, United States of America, 16 Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States of America, 17 Department of Public Health and Policy at the University of Liverpool, Liverpool, United Kingdom and the Department of Public Health and Environment at the World Health Organization, Geneva, Switzerland
Policy Forum
2011 NIH Conference on Household Air Pollution and Cookstoves
Will conduct a clinical trial across three or more Low and Middle Income Country (LMIC) settings
Will test improved stove and fuel interventions on health outcomes in exposed populations.
Will be a cooperative agreement research grant (UM1)
Published HAP FOA
MAIN COMPONENT WILL HAVE MULTIPLE FUNCTIONS
Coordinating Center:
Manage and conduct operations related to the ideation and implementation of a clinical trial.
Follow-up and report to NHLBI recruitment and implementation of the trial at the sites.
Organize Steering Committee, Investigators in person meetings, phone calls, provide payments related to protocol implementation.
Organize the DSMB in person meetings, report to DSMB and NHLBI AEs.
Provide reports of activities to the B&MGF
HAP FOA: component 1
MAIN COMPONENT WILL HAVE MULTIPLE FUNCTIONS
Propose and Supervise the implementation of the trial. The trial will:
Test the impact of improved stove and fuel interventions and, when applicable, second-hand cigarette smoke reduction on health outcomes in exposed populations.
Assess short-term (4-5 years) health outcomes: with a particular focus on women and children. Indicators of potential long-term health outcomes in this population should also be assessed.
Low birth weight and higher infant mortality, increased respiratory infections, wheezing in children, and increased rates of stroke, cardiovascular disease, lung cancer, eye disorders, burn and other injuries in adults.
Develop and implement an environmental monitoring strategy for the selected stove/fuel used in the intervention trial.
HAP FOA: component 1
Second component (with specific budget, may not be funded):
Will include a biomarker center for the development and validation of clinical, physiological, chemical and biochemical markers of exposure and pathophysiological responses.
The biomarker development and validation will be led by a PD/PI other than the one of the clinical study.
The PD(s)/PI(s) of both projects will collaborate closely to create a seamless research process and integrated data set that analyzes and connects the outcomes of the clinical trial with the biomarker data.
In some circumstances the PD/PI of the biomarker project may need to perform biomarker analyses within the LMIC where the samples have been collected.
HAP FOA: component 2
A Public/Private partnership:
NIEHS, NICHD, NCI, FIC, NHLBI
NIH-CF
BMGF
(GACC)
Budget 31+ (5) mill. Award FY 2016
Application Due Date: January 19, 2016, by 5:00 PM local time of applicant organization.
HAP FOA
Total funds available for the five year grant:
$5,000,000 TC /year for trial and overall management
$1,200,000 TC /year for biomarker center
Direct Costs $5,075,000/year, subdivided as such: Core and recruitment system funds (to a US Institution) may be
requested at up to $1,297,000 direct costs per year. Protocol (capitation) funds may be requested at up to $3,000,000 per
year. (These will be to a foreign Institution in a LMIC given by the US Core Management
Institution and are inclusive of 8 percent F&A costs for foreign grantees as stated in the information on allowable and unallowable costs for foreign grantees, in the NIH Grants Policy Statement Section 16.6).
The biomarker development and validation study (led by a US Institution) may not exceed $778,000 direct costs per year.
Budget HAP FOA